Viatris Inc
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$19.63−0.25 (-1.26%)
Close on Nov 20, 2026Market cap $22.55BP/E –Yield 2.45%
Viatris UTB Reductions by Year
UTB Reductions — Settlements with Taxing Authorities ($M)
Viatris UTB Reductions: $19.1M in FY2025, up 22.4% from a year earlier.
Latest, FY2025
19.1
Period ended Dec 31, 2025
Change on a year earlier
+22.4%
15.6 in FY2024
History
10 years
Since FY2016
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: SEC Form 10-K (2026-02-26) ↗
Reported in SEC Form 10-K Income Taxes Note.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB Reductions — Settlements with Taxing Authorities ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.1 | +22.4% | SEC Form 10-K (2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 15.6 | +642.9% | SEC Form 10-K (2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 2.10 | +425.0% | SEC Form 10-K (2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 0.40 | -99.2% | SEC Form 10-K (2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 47.3 | 0.0% | SEC Form 10-K (2024-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 47.3 | +431.5% | SEC Form 10-K (2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 8.90 | 0.0% | SEC Form 10-K (2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 8.90 | -92.1% | SEC Form 10-K (2023-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 113 | +241.9% | SEC Form 10-K (2022-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 32.9 | – | SEC Form 10-K (2021-03-01) ↗ |
Cite this data
StockData. (2026). Viatris UTB Reductions ($M), annual FY2016–FY2025 [Data set]. Compiled from Viatris SEC filings and investor materials. https://stockdatahq.com/stocks/vtrs/kpis/utb-dec-settle
See every metric in the Viatris KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?